Brief: Skye’S Cb1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss And Differentiated Mechanisms From Monlunabant, And Continues To Show Enhanced Combination With Tirzepatide With Durable Post-Treatment Weight Maintenance In Dio Model
04/09/2025 12:01
Eli Lilly and Co LLY.N: SKYE’S CB1 INHIBITOR, NIMACIMAB, DEMONSTRATES SUPERIOR WEIGHT LOSS AND DIFFERENTIATED MECHANISMS FROM MONLUNABANT, AND CONTINUES TO SHOW ENHANCED COMBINATION WITH TIRZEPATIDE WITH DURABLE POST-TREATMENT WEIGHT MAINTENANCE IN DIO MODEL SKYE BIOSCIENCE INC - NIMACIMAB + TIRZEPATIDE SHOWS 40% WEIGHT LOSS IN STUDIES SKYE BIOSCIENCE INC - NIMACIMAB REDUCES REBOUND WEIGHT GAIN POST-TREATMENT SKYE BIOSCIENCE INC - NIMACIMAB SHOWS DURABLE WEIGHT LOSS POST-TREATMENT SKYE BIOSCIENCE INC - NIMACIMAB OUTPERFORMS MONLUNABANT IN STUDIES Source text: ID:nGNXb4p4Kp Further company coverage: LLY.N
Recent news on Skye Bioscience
See all newsBrief: Skye Announces Cohort Review Committee Approved Opening Of Cohort 2 Based On Favorable Safety Data From First Four Participants Treated In Cohort 1
U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis
U.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
U.S. STOCKS ON THE MOVE-Energy firms, Estee Lauder, HMH Holding
Skye Bioscience rises as it begins testing higher doses of obesity drug